Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
GBX 377.60 -5.80 (-1.51%)
As of 12:32 PM Eastern

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for HLN.

Consensus Price Target

GBX 457
According to the 1 analysts' twelve-month price targets for Haleon, the average price target is GBX 457. The highest price target for HLN is GBX 457, while the lowest price target for HLN is GBX 457. The average price target represents a forecasted upside of 21.03% from the current price of GBX 377.60.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up

HLN Analyst Ratings Over Time

TypeCurrent Forecast
6/26/24 to 6/26/25
1 Month Ago
5/27/24 to 5/27/25
3 Months Ago
3/28/24 to 3/28/25
1 Year Ago
6/27/23 to 6/26/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 457GBX 457GBX 420GBX 356
Consensus Rating
Buy
Buy
Buy
Hold

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical Companies
Consensus Rating Score
3.00
2.81
Consensus RatingBuyModerate Buy
News Sentiment Rating
Neutral News

See Recent HLN News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/28/2025Berenberg Bank
2 of 5 stars
 Boost TargetBuyGBX 456 ➝ GBX 457+11.87%
4/18/2024HSBC
2 of 5 stars
 Initiated CoverageBuy
4/9/2024Barclays
3 of 5 stars
 Lower TargetOverweightGBX 390 ➝ GBX 383+19.28%
10/11/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetGBX 340 ➝ GBX 360+6.82%
10/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweightGBX 280-17.59%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetGBX 390 ➝ GBX 387+18.99%
8/9/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetGBX 375 ➝ GBX 370+13.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:17 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 24, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • The stock recently reached a new 12-month high, indicating strong market performance and investor confidence, with the current stock price around $5.59.
  • Haleon plc has a robust market capitalization of approximately £37.48 billion, suggesting a stable and significant presence in the consumer health sector.
  • Analysts have recently upgraded their price target for Haleon shares, reflecting positive growth expectations and a "buy" rating from Berenberg Bank.
  • The company boasts a diverse product portfolio, including well-known brands like Sensodyne and Centrum, which are built on trusted science and innovation, appealing to a broad consumer base.
  • Haleon plc has shown a solid return on equity, indicating effective management and profitability, which can be attractive to potential investors.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • The company has a relatively high P/E ratio, which may suggest that the stock is overvalued compared to its earnings, potentially leading to lower returns.
  • Haleon plc has a debt-to-equity ratio that indicates a significant amount of debt relative to its equity, which could pose risks in times of economic downturns.
  • The current ratio is below 1, suggesting that the company may face challenges in meeting its short-term liabilities, which could affect liquidity.
  • Insider transactions show that some executives have been selling shares, which could signal a lack of confidence in the company's future performance.
  • The stock has shown minimal price movement recently, indicating potential stagnation in growth, which may not attract aggressive investors.

HLN Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is GBX 457, with a high forecast of GBX 457 and a low forecast of GBX 457.

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLN shares.

According to analysts, Haleon's stock has a predicted upside of 21.03% based on their 12-month stock forecasts.

Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.


This page (LON:HLN) was last updated on 6/26/2025 by MarketBeat.com Staff
From Our Partners